Thirty-one previously untreated diabetic individuals received only human insulin (recombinant DNA) for 1 yr with no adverse reactions. The development of serum IgE antibodies to human, porcine, and bovine insulins was assessed by a sepharose radioallergoabsorbent test (RAST). Immunoglobulin (total Ig antibody) binding was assessed by a nonabsorbed species-specific radioimmunoassay. During therapy 2 patients developed IgE antibodies to human insulin as well as increased total Ig binding. The IgE antibodies to human insulin cross-reacted with porcine and bovine insulins, were transient, and were not accompanied by insulin allergy. Ig binding to insulin developed and persisted in 11 of the human insulin-treated diabetics. In comparison, 62 previously untreated diabetic persons received only purified porcine insulin (PPI, < 5 ppm proinsulin, N = 40) or a mixed bovine-porcine insulin (proinsulin < 50 ppm, N = 21). Increased Ig antibody developed in 16 of 21 patients receiving mixed bovineporcine insulin and 25 of 41 PPI-treated patients (P < 0.05). Seven of 41 PPI-treated patients and 4 of 21 mixed bovine-porcine-treated patients developed anti-insulin IgE antibodies, which were transient in 4 and persisted in 6 diabetic patients. IgE antibody levels did not correlate with total Ig antibody. These data suggest that IgE and total Ig antibodies develop less often after human insulin treatment. Also, the immunoregulation mechanisms responsible for anti-insulin IgE antibody synthesis differ from those regulating other Ig that bind to insulins. Since none of the patients in this study have developed clinical manifestations of insulin allergy or resistance, the clinical relevance of the antibody data must remain speculative, DIABETES CARE 5 (SUPPL. iy. 119-125, 1982. M any diabetic patients develop antibodies to investigational model to explore the many facets of immuinsulin within weeks to months after initiating noregulation in the diabetic patient, using insulin as the welltherapy with porcine or bovine insulins.
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any diabetic patients develop antibodies to investigational model to explore the many facets of immuinsulin within weeks to months after initiating noregulation in the diabetic patient, using insulin as the welltherapy with porcine or bovine insulins. ll2 These defined antigen probe, immune responses may represent for the dia-
The biosynthesis of human insulin (recombinant DNA), betic patient a potential complication, especially insulin al-its development as a pharmacologic agent, and the initiation lergy and/or insulin resistance. The clinical manifestations of clinical trials to investigate its clinical efficacy and pharof insulin allergy vary greatly and range from mild local cu-macology provided us the opportunity to design a prospective taneous erythema, pruritis, edema, or induration at the in-study of the immune responses to human insulin. The purpose sulin injection site to generalized urticaria, angioedema, or of this study was to compare the synthesis of specific IgE systemic anaphylaxis. 3 Insulin-specific IgE antibodies have antibodies to insulins in diabetic patients who were initiating been found in certain diabetic patients with insulin allergy. 4 ' 5 therapy with human insulin with the development of IgE High levels of anti-insulin antibodies, mostly IgG, are as-antibodies to insulins in diabetic patients who were beginning sociated with the insulin resistance syndrome, which is de-therapy with porcine and bovine insulins. The synthesis of fined as a daily insulin requirement of more than 200 U. 6 7 total Ig antibodies to human, porcine, and bovine insulins On the other hand, the development of these immune re-was also measured in these diabetic patients. These studies sponses to insulin provides the clinical immunologist a unique showed that fewer diabetic patients treated with human in- 'Mean years ± S.E. tMean % ± S.E. sulin developed increased specific IgE or total Ig antibodies to insulins as compared with those diabetic patients treated with porcine and bovine insulins.
MATERIALS AND METHODS
Subjects. In Table 1 are listed the 3 groups of diabetic patients treated with either human, porcine (PPI), or porcine-bovine (mixed) insulins. All of these diabetic patients denied previous therapy with insulin. Even though these diabetics were not preselected or matched for age, disease duration, or percentage of ideal body weight, they were quite similar, with comparable mean ages and ideal body weight. However, the duration of diagnosed illness prior to initiating insulin therapy was somewhat less in those patients selected for therapy with PPI.
Sera. Blood samples were obtained before and at 1-or 2-mo intervals after starting insulin therapy in all study patients. Sera was separated, frozen, and stored at -70°C until studied.
Insulins. The human, PPI, and mixed porcine-bovine insulins were provided for patient use by the Lilly Research Laboratories. The PPI contained less than 5 PPM proinsulin and less than 0.5% bovine insulin; whereas, the mixed porcine-bovine insulin contained less than 50 PPM proinsulin and greater than 80% bovine insulin.
IgE insulin antibodies. The radioallergoabsorbent test (RAST) was utilized to measure specific IgE antibodies to human, porcine, and bovine insulins, as previously described. 8 The species-specific insulins, which were provided by Dr. R. Chance, Lilly Research Laboratories, were individually covalently coupled to cyanogen bromide activated sepharose beads. After incubation of the insulin-sepharose with patient's serum and washing three times, 125 I rabbit anti-human IgE antibody (Pharmacia, Uppsala, Sweden) was added. After washing procedures, the radioactivity bound to the antibodyantigen complex on the sepharose particles was counted and the data expressed as percentage counts bound to total counts added (% B/T). Sera from normal subjects who had never received insulin had a mean 3.5% ± 1.7% B/T, and 7% B/ T (2 standard deviations above the mean) was considered the upper limits of normal.
Total Ig insulin antibody. Species-specific total Ig antibody (mostly IgG) was measured by a nonabsorbed species-specific radioimmunoassay with 125 I insulin as previously described in detail by Fineberg. 9 The antibody activity was expressed as 
RESULTS
The development of IgE antibodies to human insulin in the 31 patients treated with human insulin is shown in Figure  1 . None of these patients had elevated IgE antibodies prior to beginning insulin therapy. Two of the 31 diabetic patients developed increased IgE insulin antibody (greater than 7% B/T), which peaked 2-6 mo after onset of human insulin treatment and returned towards normal by 10 mo of therapy. These 2 patients did not develop any signs or symptoms of insulin allergy or adverse reactions to the human insulin; nor did any of the other 29 subjects treated with human insulin.
As shown in Figures 2 and 3, these same 2 diabetic patients' sera had comparable and transient increases in IgE antibodies to porcine and bovine insulins. These data indicate that the IgE antibodies to human insulin that developed during human insulin therapy cross-reacted with porcine and bovine insulins.
The development of total Ig antibodies to human insulin is shown in Figure 4 . Increased Ig antibodies were found in 10 of the 31 patients who were treated with human insulin, including the 2 patients who had increased IgE antibody. The Ig antibodies to human insulin gradually increased during the initial 6 mo of the study and did not appear to correlate with development of species-specific anti-insulin IgE antibodies. cine insulin in those patients treated with PPL Unlike the human-insulin-treated patients, 3 of these diabetic patients had increased IgE antibodies to porcine insulin before starting insulin therapy even though these patients denied previous insulin treatment. After starting PPI therapy, 1 diabetic continued to synthesize increased IgE antibodies to porcine insulin but in the other 2 patients serum IgE antibody to insulin decreased after initiating the insulin therapy. Several patterns of increased IgE antibody to porcine insulin were recognized. Thirty-four of the 41 diabetic patients showed no rise in IgE antibodies. Two patients developed a transient increase of IgE antibodies at 2-4 mo and then returned to normal values after 6-8 mo of insulin therapy, but 3 patients sustained elevated IgE antibody during the 12-mo study. One diabetic gradually developed increased IgE antibodies during the 12 mo of insulin treatment. In spite of increased IgE antibodies, none of these subjects have manifested any clinical allergic or adverse reactions to insulin. Figure 6 shows the 6 patients with increased IgE antibodies to bovine insulin after therapy with PPI. Five of these 6 diabetics also had increased IgE antibodies to bovine insulin, documenting that these IgE antibodies cross-react with both porcine and bovine insulins. However, one patient developed IgE antibodies to only porcine insulin and another had IgE antibodies to only bovine insulin.
Figures 7 and 8 depict the development of IgE antibodies to porcine and bovine insulin in the 21 diabetics treated with the mixed porcine-bovine insulin. Two patients had increased IgE antibodies to porcine insulin but not to bovine insulin before starting insulin, and both patients denied prior insulin therapy. One subject sustained the increased IgE antibody to porcine insulin during insulin therapy, but unlike the other subjects, this patient's porcine IgE antibody did not cross-react with bovine insulin. The transient nature of the increase in IgE antibody at 2-4 mo of insulin therapy was again noted. Table 2 summarizes the development of IgE and total Ig antibodies to human, porcine, and bovine insulins in patients treated with human, PPI, and porcine-bovine insulins. Whereas 6% of patients treated with human insulin developed increased IgE antibodies, 17% and 19% of those treated with PPI or mixed insulins, respectively, had increased IgE antibodies to insulin. A greater percentage of patients treated with PPI or the mixed porcine-bovine insulins (61% and 76%, respectively) developed total Ig (mostly IgG) antibodies to the several insulins than those patients (35%) who synthesized IgE antibodies to insulin after therapy with human insulin.
-i ince fewer diabetic subjects treated with human insulin developed increased IgE or total Ig antibodies to insulin as compared to patients treated with PPI or mixed porcine-bovine insulins, it appears that human insulin was less immunogenic than porcine or bovine insulin. This observation was not unexpected since human insulin is identical chemically to natural human insulin, and the porcine and bovine insulins have amino acid differences. 10 If human insulin (recombinant DNA) is identical to naturally occurring human insulin, then theoretically it should be considered "self," and there should be little if any antibody synthesis to a native antigen. Whether this expression of antibody synthesis to human insulin in these diabetic patients represents autoimmunity or another phenomenon related to the subcutaneous route of insulin administration or some other unidentified mechanism must remain speculative at this time. There may be other possible explanations for these results. Since diabetic patients with a personal or family history of allergic diseases such as allergic rhinitis or asthma were not excluded from the study, it is possible that patients prone to increased IgE synthesis were inadvertently included in the study group. This does not appear to be the case since total serum IgE levels were not elevated in any of those diabetics who developed increased IgE antibodies to insulin. It is also possible that the patients who developed increased IgE antibodies to insulin may have a genetic predisposition to synthesize IgE antibodies. It has been suggested that specific IgE antibody responses to ragweed pollen are influenced by immune response genes, and the IgE antibody response to ragweed pollen was linked to the histocompatibility (HLA) locus.
11 HLA typing will be performed on our study patients, but these studies have not been completed.
It should be emphasized that less than 20% of the diabetic subjects developed IgE antibodies during therapy with hu- man, porcine, or bovine insulins, yet 61-76% of the patients treated with porcine or bovine insulin developed total Ig (mostly IgG) insulin antibodies. In those patients treated with human insulin, 6% developed IgE antibodies, whereas 35% developed total Ig insulin antibodies. Thus, IgE antibody synthesis did not correlate with total Ig antibody synthesis and indicated that the immunoregulation mechanism responsible for anti-insulin IgE antibody differs from those regulating other Ig that can bind to insulin. Since none of the patients in the three study groups have developed clinical manifestations of insulin allergy, resistance, or other potential immune-mediated complications of diabetes, the clinical relevance of the observed increased antibody levels must remain speculative. It is our anticipation that these prospective studies will be continued and the clinical data will be forthcoming in the not too distant future.
